DIAN Data Resource Requests

In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-D1004), the full request has been submitted and is either approved, disapproved or in process.

Displaying 211 - 220 of 319

Investigator:John Ringman

Title:Identification of cerebral microhemorrhages in persons carrying familial AD mutations

Date of Request:08/22/2011

Status:Pending

ID:DIAN-D1104

Aim 1:Ascertain the prevalence of CAA in FAD using the clinical radiological interpretation of the presence of microhemorrhages on susceptibility-weighted MRI images (SWI)

Aim 2:to relate the location of microhemorrhages to amyloid deposition as measured using PIB scans

Aim 3:explore the relationship of microhemorrhages to FAD mutation type, adjusted age, CDR sum of boxes score, gender, and APOE genotype.

Investigator:John Ringman

Title:Prevalence of REM Sleep Behavior Disorder and other DLB symptoms in Familial Alzheimers Disease

Date of Request:11/2/2011

Status:A

ID:z

Aim 1:ascertain how common symptoms of RBD are in early symptomatic and demented persons carrying FAD mutations

Aim 2:to assess whether symptoms of RBD are more common in FAD mutation carriers relative to their non-mutation carrying kin

Aim 3:to compare the prevalence of other symptoms of DLB (hallucinations, fluctuations, and Parkinsonism) between FAD mutation carriers (MCs) and non-carriers (NCs).

Investigator:Reisa Sperling

Title:Relationship of PiB-PET amyloid imaging and default network fc-MRI in DIAN subjects

Date of Request:11/15/2011

Status:A

ID:DIAN-D1101

Aim 1:To investigate whether level of cortical PiB retention is related to default network dysconnectivity across the spectrum of DIAN participants (ADAD mutation carriers, non-carriers, asymptomatic and symptomatic).

Aim 2:To determine whether ADAD mutation carriers demonstrate impaired connectivity compared to non-carriers, independent of PiB retention.

Aim 3:To elucidate the temporal relationship of the emergence of default network dysfunction in ADAD mutation carriers to their expected age of onset.

Investigator:Randall Bateman MD

Title:Development and validation of evidence-based criteria for estimating age of onset in the DIAN study

Date of Request:11/27/2011

Status:A

ID:DIAN-D1110

Aim 1:Development and validation of evidence-based estimates for expected age of onset within ADAD families

Aim 2:Pedigree analysis of DIAN families to directly assess heritability and examine the effects of additional prognostic variables in modifying familial age of onset

Investigator:Morris

Title:Imaging Committee Presentations at 2012 Human Amyloid Imaging Meeting

Date of Request:12/19/2011

Status:A

ID:-

Aim 1:The DIAN Imaging Committee is presenting 2 abstracts at the 2012 Human Amyloid Imaging Meeting, titiles are listed below.

Aim 2:[11C] PIB, FDG and MR findings of preclinical AD in the DIAN cohort

Aim 3:Reference tissue normalization in autosomal dominant AD: Comparison of cerebellar versus brainstem referencing for [11C]PIBin the DIAN cohort

Investigator:Andrei Vlassenko

Title:Regional beta-amyloid deposition in cognitively normal adults

Date of Request:2/7/2012

Status:IP

ID:DIAN-D1201

Aim 1:Examine regional differences in PIB BP in PIB-negative older compared to younger adults

Investigator:Christopher Leatherday

Title:An Investigation of Optimised Hippocampal Masking Techniques in Alzheimer's Disease Diagnosis.

Date of Request:3/7/2012

Status:IA

ID:DIAN-D1202

Aim 1:Verify the optimised pes hippocampal masking results obtained by Mosconi et al. in their 2005 paper: “Reduced hippocampal metabolism in MCI and AD: Automated FDG-PET image analysis”.

Aim 2:Compare the efficacy of a volumetric pes hippocampal mask to one that includes the whole hippocampus; in terms of their ability to distinguish between functional brain images of Alzheimer’s disease, mild cognitive impairment and healthy elderly subjects.

Investigator:David Teplow

Title:Behavioral and mood disturbances in prodromal familial Alzheimer’s disease

Date of Request:3/15/2012

Status:A

ID:DIAN-D1203

Aim 1:Compare the frequency of behavioral disturbances on the NPI-Q between asymptomatic FAD mutation carriers and non-carriers

Aim 2:Compare the severity of behavioral disturbances on the NPI-Q between asymptomatic FAD mutation carriers and non-carriers

Aim 3:Compare the level of self-rated depression (GDS) between asymptomatic FAD mutation carriers and non-carriers

Aim 4Compare the rate of self-rated depression and informant-rated depression in FAD mutation carriers

Investigator:Reisa Sperling, MD

Title:Relationship of CSF markers to Functional Connectivity in DIAN

Date of Request:8/7/2012

Status:A

ID:DIAN-D1101

Aim 1:(This is an amendment to add the CSF biomarkers to our approved PiB-fc-MRI project). To elucidate the temporal relationship of the emergence of default network dysfunction in ADAD mutation carriers to CSF markers of Abeta, phospho-tau and tau.

Investigator:Randall J. Bateman, M.D.

Title:DIAN Treatment Trials - Cognitive Test Battery

Date of Request:8/8/2012

Status:A

ID:DIAN-D1100

Aim 1:Analyze the DIAN cognitive data set to determine the most effective cognitive test measures to use in the DIAN Treatment Trials while allowing for historical run-in comparisons and some measure of continuity between the studies.

Aim 2:Compare the DIAN Data to existing, published data (e.g. RUSH, ABEL) to determine a cognitive composite test battery that overlaps well with those measures selected for use in other large, planned secondary prevention trials (i.e., A4 and API trials).